Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Incorrect product administration duration? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Incorrect product administration duration have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.0% of all adverse event reports for OCRELIZUMAB.

11
Reports of Incorrect product administration duration with OCRELIZUMAB
0.0%
of all OCRELIZUMAB reports
0
Deaths
0
Hospitalizations

How Dangerous Is Incorrect product administration duration From OCRELIZUMAB?

Of the 11 reports.

Is Incorrect product administration duration Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Incorrect product administration duration?

ETONOGESTREL (3,974) POLYETHYLENE GLYCOL 3350 (2,129) NIRMATRELVIR\RITONAVIR (744) DOCOSANOL (634) LANSOPRAZOLE (564) LOPERAMIDE (543) NAPROXEN (499) INSULIN LISPRO (479) DICLOFENAC (362) OMEPRAZOLE (302)

Which OCRELIZUMAB Alternatives Have Lower Incorrect product administration duration Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Incorrect product administration duration Reports All Drugs Causing Incorrect product administration duration OCRELIZUMAB Demographics